Showing 2501-2510 of 5909 results for "".
- Holland Foundation for Sight Restoration Appoints Kila Hanrahan Director of Developmenthttps://modernod.com/news/holland-foundation-for-sight-restoration-appoints-kila-hanrahan-director-of-development/2480875/Kila Hanrahan, who has more than a decade experience in fundraising initiatives, has joined the Holland Foundation for Sight Restoration as Director of Development. “We are very excited to have Kila joining the Holland Foundation as the first employee,” said Holland Fo
- Qlaris Bio Reports Phase 2 Clinical Trial Results Demonstrating Favorable Safety and Tolerability Profile and Positive Efficacy Signal for QLS-101https://modernod.com/news/qlaris-bio-reports-phase-2-clinical-trial-results-demonstrating-favorable-safety-and-tolerability-profile-and-positive-efficacy-signal-for-qls-101/2480871/Qlaris Bio announced results from QC-201, a first-in-human, phase 2 clinical trial of QLS-101, the company’s investigational therapy for lowering IOP in the treatment of glaucoma. Study findings demonstrated a favorable safety and tolerability profile for QLS-101, including no evi
- Nova Eye Medical Reports Canaloplasty Data Demonstrating Sustained Reduction in IOP with iTrackhttps://modernod.com/news/nova-eye-medical-reports-canaloplasty-data-demonstrating-sustained-reduction-in-iop-with-itrack/2480849/Nova Eye Medical reported the recent publication of three investigator-led, retrospective case series which evaluated the long-term effectiveness of canaloplasty in patients with open-angle glaucoma (OAG) over 36- and 48-month periods, and in post-keratoplasty patients. Performed b
- Tarsus Presents New Findings From Two Studies That Demonstrate the Impact of Demodex Blepharitis at the ARVO 2022 Annual Meetinghttps://modernod.com/news/tarsus-presents-new-findings-from-two-studies-that-demonstrate-the-impact-of-demodex-blepharitis-at-the-arvo-2022-annual-meeting/2480847/Tarsus Pharmaceuticals, Inc. presented data from its Atlas Continuation study on the negative impact Demodex blepharitis has on daily life and visual function among certain patient groups, as well as preliminary findings from the Pandora study on the coexisting bacterial burden for patients with
- Clearside Biomedical Poster Presentation at ARVO 2022 Annual Meeting Demonstrates Versatility of Suprachoroidal Delivery Technologyhttps://modernod.com/news/clearside-biomedical-poster-presentation-at-arvo-2022-annual-meeting-demonstrates-versatility-of-suprachoroidal-delivery-technology/2480845/Clearside Biomedical, Inc. announced that several poster presentations were delivered on Clearside’s proprietary suprachoroidal delivery platform, XIPERE®, and gene therapy delivery utilizing Clearside’s SCS Microinjector® at the Association for Research in Vision and Ophthalm
- Apellis Announces Detailed 18-Month Results from Phase 3 DERBY and OAKS Studies of Pegcetacoplan for Geographic Atrophy (GA)https://modernod.com/news/apellis-announces-detailed-18-month-results-from-phase-3-derby-and-oaks-studies-of-pegcetacoplan-for-geographic-atrophy-ga-at-arvo/2480830/Apellis Pharmaceuticals announced detailed, longer-term data from the phase 3 DERBY and OAKS studies of intravitreal pegcetacoplan, an investigational, targeted C3 therapy, for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). Monthly and
- Tarsus Announces Positive Topline Data from Saturn-2 Phase 3 Trial of TP-03 for the Treatment of Demodex Blepharitishttps://modernod.com/news/tarsus-announces-positive-topline-data-from-saturn-2-phase-3-the-second-pivotal-trial-of-tp-03-for-the-treatment-of-demodex-blepharitis/2480827/Tarsus Pharmaceuticals announced that TP-03 (lotilaner ophthalmic solution, 0.25%) met the primary endpoint and all secondary endpoints in the Saturn-2 pivotal phase 3 trial with a favorable safety profile, reinforcing its ability to resolve Demodex blepharitis. With these
- Tarsus Presents Results of Two Studies Highlighting Demodex Blepharitis Patient Impact and Burden at the ASCRS 2022https://modernod.com/news/tarsus-presents-results-of-two-studies-highlighting-demodex-blepharitis-patient-impact-and-burden-at-the-ascrs-2022-annual-meeting/2480803/Tarsus Pharmaceuticals presented data from its Atlas Continuation study on the negative impacts to daily life and visual function, and preliminary findings from its Pandora study on pathogenic bacterial count, for patients with Demodex blepharitis at the American S
- CorneaGen Releases New DSEK Surgery Device to Help Streamline DSEK Surgerieshttps://modernod.com/news/corneagen-advances-next-generation-of-dsek-surgery-innovation/2480789/CorneaGen announced the release of the EndoSerter-PL, a new FDA approved, single-use graft insertion device preloaded with processed tissue to help streamline DSEK surgeries. “We’re incredibly excited to deliver the EndoSerter-PL, our latest innovation in
- Zeiss Announces FDA Clearance of the Quatera 700 Phaco Devicehttps://modernod.com/news/zeiss-announces-fda-clearance-of-the-quatera-700-phaco-technology/2480779/Zeiss announced that the FDA has cleared the Quatera 700, which includes the Zeiss patented Quattro Pump designed to deliver chamber stability independent of IOP and flow. “What excites me the most about the Quatera 700 is the Quattro pump’